AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19188561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigidfix cross‐pin and Intrafix tibial expansion sheath with a tapered expansion screw
Number of subjects: 120
Study 19188561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigidfix femoral and BioScrew interference screw tibial fixation
Number of subjects: 120
Study 19188561 — intervention group
Group type: EXPERIMENTAL
Intervention: BioScrew femoral and Intrafix tibial fixation
Number of subjects: 120
Study 19188561 — intervention group
Group type: EXPERIMENTAL
Intervention: BioScrew fixation into both tunnels
Number of subjects: 120
Study 19188561 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 18089984 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CASI (Audio computer-assisted self-interviewing)
Number of subjects: 821
Study 14985864 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized uptake value (SUV) images acquired from 30 to 35 min after FMZ administration
Number of subjects: 15
Study 14985864 — intervention group
Group type: COMPARATOR
Intervention: Distribution volume (DV) images
Number of subjects: 15
Study 12271408 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOL PET
Number of subjects: 18
Study 9613300 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 13
Study 9613300 — intervention group
Group type: COMPARATOR
Intervention: Coulter Max‐M
Number of subjects: 13
Study 9613300 — intervention group
Group type: COMPARATOR
Intervention: HemoCue and Coulter Max‐M
Number of subjects: 13
Study 7653818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (5 mg/mL)
Number of subjects: 60
Study 7653818 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (5 mg/mL)
Number of subjects: 60
Study 2667156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 95
Study 2667156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily)
Number of subjects: 95
Study 314392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (500 mg capsules)
Number of subjects: 600
Study 314392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (750 mg capsules)
Number of subjects: 600
Study 314392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 30572979 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 456
Study 30572979 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD
Number of subjects: 456
Study 30572979 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT
Number of subjects: 456
Study 30572979 — intervention group
Group type: COMPARATOR
Intervention: C-Tb, PPD, QFT
Number of subjects: 456
Study 27535352 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg clonidine orally
Number of subjects: 50
Study 27535352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26448622 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (50 mg Alteplase)
Number of subjects: 24
Study 26448622 — intervention group
Group type: COMPARATOR
Intervention: Control (no tPA)
Number of subjects: 24
Study 23357838 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg 4 times daily for 6 days)
Number of subjects: 20
Study 23357838 — intervention group
Group type: COMPARATOR
Intervention: Dalcetrapib alone (without probenecid)
Number of subjects: 20
Study 16716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 12
Study 16716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 12
Study 15679255 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (specific dosage and duration not mentioned)
Number of subjects: 0
Study 15679255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and gemcitabine (specific details not mentioned)
Number of subjects: 0
Study 11087215 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 8
Study 8799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg sublingual
Number of subjects: 23
Study 8799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 10 mg
Number of subjects: 23
Study 8799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg orally twice daily
Number of subjects: 23
Study 8799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 20 mg twice daily
Number of subjects: 23
Study 1459316 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril (10 mg/day)
Number of subjects: 10
Study 1459316 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 3977556 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 0
Study 30860653 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 222
Study 30860653 — intervention group
Group type: COMPARATOR
Intervention: Active control group (relaxation training)
Number of subjects: 222
Study 28730753 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR score-based algorithm
Number of subjects: 2639
Study 28730753 — intervention group
Group type: COMPARATOR
Intervention: Routine imaging
Number of subjects: 2639
Study 28730753 — intervention group
Group type: COMPARATOR
Intervention: Selective imaging after clinical reassessment
Number of subjects: 2639
Study 25701070 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography before CEA (Group A)
Number of subjects: 426
Study 25701070 — intervention group
Group type: COMPARATOR
Intervention: No coronary angiography before CEA (Group B)
Number of subjects: 426
Study 23536611 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 11897
Study 20647958 — intervention group
Group type: EXPERIMENTAL
Intervention: Keishibukuryogan
Number of subjects: 120
Study 20647958 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamishoyosan
Number of subjects: 120
Study 20647958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 18823799 — intervention group
Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 42
Study 18823799 — intervention group
Group type: COMPARATOR
Intervention: Open reduction-internal fixation (ORIF)
Number of subjects: 42
Study 17211497 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training plus standard care (ST group)
Number of subjects: 62
Study 15931690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famciclovir 250 mg twice daily
Number of subjects: 469
Study 15931690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 11789262 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Taixian tablet (CTXT)
Number of subjects: 60
Study 11789262 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium hypoglaucum tablet
Number of subjects: 60
Study 11789262 — intervention group
Group type: COMPARATOR
Intervention: Polyactin‐A tablet
Number of subjects: 60
Study 9081688 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/d micronized 17 beta-estradiol
Number of subjects: 40
Study 9081688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1608523 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg bid im starting one day before surgery and continuing until the 7th postoperative day)
Number of subjects: 81
Study 1608523 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU bid sc starting two hours before surgery and continuing likewise for 7 days)
Number of subjects: 81
Study 3936097 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (450 mg)
Number of subjects: 18
Study 3936097 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (900 mg)
Number of subjects: 18
Study 3936097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (L)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid plus Letrozole (ZL)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZL) vs Tamoxifen (T)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (L) vs Tamoxifen (T)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZL) vs Letrozole (L)
Number of subjects: 1065
Study 31164265 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1065
Study 31164265 — intervention group
Group type: COMPARATOR
Intervention: Grade 3–4 side effects
Number of subjects: 1065
Study 29874375 — intervention group
Group type: COMPARATOR
Intervention: Standard fluorouracil-based preoperative chemoradiotherapy (CRT) alone (control arm)
Number of subjects: 1236
Study 29874375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin followed by TME and adjuvant chemotherapy (experimental arm)
Number of subjects: 1236
Study 29874375 — intervention group
Group type: EXPERIMENTAL
Intervention: TME plane quality (mesorectal, intramesorectal, muscularis propria)
Number of subjects: 1236
Study 29874375 — intervention group
Group type: EXPERIMENTAL
Intervention: TME plane assessment by pathologists
Number of subjects: 1236
Study 27471048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (LDCT)
Number of subjects: 4037
Study 27471048 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 4037
Study 24648285 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mother-centered interventions for obesity prevention
Number of subjects: 0
Study 24648285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22410207 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 340
Study 20338894 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of intracranial pressure (ICP) variability during the first 48 hours
Number of subjects: 38
Study 20338894 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving averages display in bedside monitoring
Number of subjects: 38
Study 18710726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus placebo, oxybutynin, or bladder training with online feedback (urge syndrome)
Number of subjects: 202
Study 18710726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus pelvic floor training with online feedback (dysfunctional voiding)
Number of subjects: 202
Study 18710726 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (urge syndrome and dysfunctional voiding)
Number of subjects: 202
Study 15972357 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drug (DMARD) therapy
Number of subjects: 366
Study 15972357 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 366
Study 15972357 — intervention group
Group type: COMPARATOR
Intervention: 5-year assessment
Number of subjects: 366
Study 12133434 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-MWT exercise training (twice a day for 8 weeks)
Number of subjects: 60
Study 12133434 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-MWT exercise training
Number of subjects: 60
Study 12133434 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medication only)
Number of subjects: 60
Study 10613616 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 0.25 mg levonorgestrel once daily)
Number of subjects: 10
Study 10613616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7784306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 1 (Biltricide) at full dose (40 mg kg‐1)
Number of subjects: 506
Study 7784306 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 2 (Distocide) at full dose (40 mg kg‐1)
Number of subjects: 506
Study 7784306 — intervention group
Group type: COMPARATOR
Intervention: Brand 1 (Biltricide) at half dose (20 mg kg‐1)
Number of subjects: 506
Study 7784306 — intervention group
Group type: COMPARATOR
Intervention: Brand 2 (Distocide) at half dose (20 mg kg‐1)
Number of subjects: 506
Study 2019862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (2 g, once a day, i.v.)
Number of subjects: 40
Study 2019862 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg, twice a day, p.o.)
Number of subjects: 40
Study 6924538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin (3 g)
Number of subjects: 388
Study 6924538 — intervention group
Group type: COMPARATOR
Intervention: Two-week amoxicillin treatment (250 mg three times a day)
Number of subjects: 388
Study 30579065 — intervention group
Group type: EXPERIMENTAL
Intervention: Video glasses
Number of subjects: 23
Study 28233009 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 21
Study 28233009 — intervention group
Group type: COMPARATOR
Intervention: Sham Kinesio taping
Number of subjects: 21
Study 25043339 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score 63 (GRS63)
Number of subjects: 8067
Study 25043339 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score 16 (GRS16)
Number of subjects: 8067
Study 25043339 — intervention group
Group type: COMPARATOR
Intervention: Base model (age, weight, height)
Number of subjects: 8067
Study 25043339 — intervention group
Group type: COMPARATOR
Intervention: BMD-adjusted models
Number of subjects: 8067
Study 25043339 — intervention group
Group type: EXPERIMENTAL
Intervention: Net reclassification improvements with GRSs
Number of subjects: 8067
Study 23444094 — intervention group
Group type: EXPERIMENTAL
Intervention: BEX Runner palm cooling device
Number of subjects: 12
Study 23444094 — intervention group
Group type: COMPARATOR
Intervention: Control (no palm cooling)
Number of subjects: 12
Study 21319291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin treatment
Number of subjects: 498
Study 21319291 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids treatment
Number of subjects: 498
Study 21319291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 498
Study 21319291 — intervention group
Group type: COMPARATOR
Intervention: Vincristine dose
Number of subjects: 498
Study 20084980 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17972431 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Mutual Caring Interactions (DMCI) scale
Number of subjects: 525
Study 17972431 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36v2
Number of subjects: 525
Study 17972431 — intervention group
Group type: EXPERIMENTAL
Intervention: DMCI constructs
Number of subjects: 525
Study 15139502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked green banana (n = 19)
Number of subjects: 57
Study 15139502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (n = 17)
Number of subjects: 57
Study 15139502 — intervention group
Group type: COMPARATOR
Intervention: Rice diet alone (n = 21)
Number of subjects: 57
Study 11924916 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 0
Study 11924916 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 0
Study 9021442 — intervention group
Group type: EXPERIMENTAL
Intervention: tolbutamide R.A.N.
Number of subjects: 22
Study 9021442 — intervention group
Group type: COMPARATOR
Intervention: rastianon Hoechst
Number of subjects: 22
Study 7938234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine (up to 10.08 g)
Number of subjects: 0
Study 7938234 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (high doses)
Number of subjects: 0
Study 7938234 — intervention group
Group type: COMPARATOR
Intervention: Alanine (designated as placebo)
Number of subjects: 0
Study 3203045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (5 mg day-1)
Number of subjects: 28
Study 3203045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg day-1)
Number of subjects: 28
Study 3203045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31313402 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX injection every 4 weeks
Number of subjects: 250
Study 31313402 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection every 4 weeks
Number of subjects: 250
Study 31313402 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 250
Study 31313402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 29584518 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n=7), all sets with 10RM load
Number of subjects: 21
Study 29584518 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% load reduction (RED 5, n=7)
Number of subjects: 21
Study 29584518 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% load reduction (RED 10, n=7)
Number of subjects: 21
Study 28410787 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NTG ointment applied at the anal canal twice daily for 8 weeks
Number of subjects: 105
Study 28410787 — intervention group
Group type: COMPARATOR
Intervention: Classical conservative therapy (sitz bath, stool softener, local anesthetic)
Number of subjects: 105
Study 26180222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention (Aurora)
Number of subjects: 302
Study 26180222 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (ESC)
Number of subjects: 302
Study 26180222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 8 weeks of nicotine replacement therapy (NRT) patch
Number of subjects: 302
Study 23549909 — intervention group
Group type: EXPERIMENTAL
Intervention: OM 40/AML 10/HCTZ 25 mg triple-combination treatment
Number of subjects: 2492
Study 21912659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 84
Study 21912659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 84
Study 21912659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 18349202 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of dexamethasone i.v. before surgery
Number of subjects: 50
Study 18349202 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo i.v. before surgery
Number of subjects: 50
Study 16339480 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional vascular risk factors for eligibility in stroke prevention trials
Number of subjects: 0
Study 16339480 — intervention group
Group type: COMPARATOR
Intervention: No additional vascular risk factors
Number of subjects: 0
Study 14703215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (0.05%) mouth rinse
Number of subjects: 60
Study 14703215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) mouth rinse
Number of subjects: 60
Study 14703215 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan (0.3%) mouth rinse
Number of subjects: 60
Study 14703215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouth rinse)
Number of subjects: 60
Study 10981070 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 0
Study 10981070 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 10981070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium-channel blockers
Number of subjects: 0
Study 8877026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg)
Number of subjects: 10
Study 8877026 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200 mg)
Number of subjects: 10
Study 8877026 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim)
Number of subjects: 10
Study 1676621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 40
Study 1676621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1676621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 6670581 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 90
Study 6670581 — intervention group
Group type: COMPARATOR
Intervention: melitracen-flupentixol
Number of subjects: 90
Study 3981325 — intervention group
Group type: EXPERIMENTAL
Intervention: sucrose 1.75 gm/kg
Number of subjects: 16
Study 3981325 — intervention group
Group type: COMPARATOR
Intervention: placebo (aspartame in equivalent sweetness)
Number of subjects: 16
Study 29650949 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal IgG antibodies against Fel d 1 (single dose)
Number of subjects: 0
Study 29650949 — intervention group
Group type: COMPARATOR
Intervention: Conventional SIT (not specified in detail)
Number of subjects: 0
Study 27633841 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes that subsequently developed PVD (1.81 ± 0.61 %W; P = .146)
Number of subjects: 28
Study 27633841 — intervention group
Group type: EXPERIMENTAL
Intervention: Following PVD
Number of subjects: 28
Study 27633841 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who chose limited vitrectomy
Number of subjects: 28
Study 27633841 — intervention group
Group type: EXPERIMENTAL
Intervention: After vitrectomy
Number of subjects: 28
Study 27633841 — intervention group
Group type: COMPARATOR
Intervention: Control fellow eyes
Number of subjects: 28
Study 24714359 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib therapy
Number of subjects: 54
Study 24714359 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/CIK plus erlotinib
Number of subjects: 54
Study 22588140 — intervention group
Group type: EXPERIMENTAL
Intervention: 75NC007 intravaginal device
Number of subjects: 55
Study 22588140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study 20822474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at acupuncture point spleen 6 (SP6) on both legs during contractions for 30 minutes
Number of subjects: 212
Study 20822474 — intervention group
Group type: COMPARATOR
Intervention: Light touch at SP6 on both legs during the same period
Number of subjects: 212
Study 20822474 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 212